Accelerate Diagnostics (MEX:AXDX) Cyclically Adjusted Revenue per Share: MXN24.53 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics Cyclically Adjusted Revenue per Share?

Accelerate Diagnostics MEX:AXDX 12 Cyclically Adjusted Revenue per Share is MXN24.53 as of Dec. 2024. GuruFocus rates MEX:AXDX with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Accelerate Diagnostics's adjusted revenue per share for the three months ended in Dec. 2024 was MXN2.330. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN24.53 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-09), Accelerate Diagnostics's current stock price is MXN1.75. Accelerate Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was MXN24.53. Accelerate Diagnostics's Cyclically Adjusted PS Ratio of today is 0.07.


Accelerate Diagnostics  (MEX:AXDX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Accelerate Diagnostics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.75/24.53
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Accelerate Diagnostics Cyclically Adjusted Revenue per Share Related Terms


Accelerate Diagnostics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Accelerate Diagnostics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Cyclically Adjusted Revenue per Share Chart

Accelerate Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.66 16.32 20.55 22.96 24.53

Accelerate Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.96 23.63 24.00 24.31 24.53

MEX:AXDX vs MSIU, BIOLQ, AFIB: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Accelerate Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Cyclically Adjusted PS Ratio falls into.


MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accelerate Diagnostics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Accelerate Diagnostics's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.33/315.6050*315.6050
=2.330

Current CPI (Dec. 2024) = 315.6050.

Accelerate Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.048 236.119 0.064
201506 0.067 238.638 0.089
201509 0.348 237.945 0.462
201512 0.082 236.525 0.109
201603 0.548 238.132 0.726
201606 0.072 241.018 0.094
201609 0.091 241.428 0.119
201612 0.156 241.432 0.204
201703 1.923 243.801 2.489
201706 2.359 244.955 3.039
201709 2.716 246.819 3.473
201712 7.501 246.524 9.603
201803 2.615 249.554 3.307
201806 6.157 251.989 7.711
201809 4.681 252.439 5.852
201812 6.601 251.233 8.292
201903 6.247 254.202 7.756
201906 6.368 256.143 7.846
201909 8.219 256.759 10.103
201912 11.973 256.974 14.705
202003 10.014 258.115 12.244
202006 8.846 257.797 10.830
202009 14.014 260.280 16.993
202012 10.814 260.474 13.103
202103 8.795 264.877 10.479
202106 9.123 271.696 10.597
202109 10.498 274.310 12.078
202112 10.364 278.802 11.732
202203 8.692 287.504 9.542
202206 10.190 296.311 10.854
202209 6.843 296.808 7.276
202212 5.943 296.797 6.320
202303 5.156 301.836 5.391
202306 4.549 305.109 4.705
202309 3.982 307.789 4.083
202312 3.525 306.746 3.627
202403 2.523 312.332 2.549
202406 2.372 314.175 2.383
202409 2.351 315.301 2.353
202412 2.330 315.605 2.330

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN24.53 mean?
Accelerate Diagnostics (MEX:AXDX) has a Cyclically Adjusted Revenue per Share of MXN24.53 as of Dec. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Cyclically Adjusted Revenue per Share too high?
Accelerate Diagnostics' current Cyclically Adjusted Revenue per Share is MXN24.53. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Cyclically Adjusted Revenue per Share compare to MSIU and BIOLQ?
Accelerate Diagnostics' Cyclically Adjusted Revenue per Share of MXN24.53 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Cyclically Adjusted Revenue per Share is MXN24.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Cyclically Adjusted Revenue per Share of MXN24.53. The current Cyclically Adjusted Revenue per Share is MXN24.53. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Cyclically Adjusted Revenue per Share is MXN24.53 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price